Antithrombotic Strategies in Patients with Cancer

• references

• 1 Sproul EE. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 1938; 34: 566-585
• 2 Ambrus JL, Ambrus CM, Mink IB, Pickren JW. Causes of death in cancer patients. J Med 1975; 06: 61-64
• 3 Kakkar VV, Howe CT, Nicolaides AN, Renney JTG, Clarke MB. Deep vein thrombosis of the leg. Is there a “high risk” group?. Am J Surg 1970; 120: 527-530
• 4 Hills NH, Pflug JJ, Jeyasingh K, Boardman L, Calnan JS. Prevention of deep vein thrombosis by intermittent pneumatic compression of calf. Br Med J 1972; 01: 131-135
• 5 Walsh JJ, Bonnar J, Wright FW. A study of pulmonary embolism and deep vein thrombosis after major gynaecological surgery using labelled fibrinogen-phlebography and lung scanning J Obstet Gynaecol Br Commonw. 1974; 81: 311-316
• 6 Sue-Ling HM, Johnston D, McMahon MU, Philips PR, Davies JA. Preoperative identification of patients at high risk of deep venous thrombosis after elective major abdominal surgery. Lancet 1986; 01: 1173-1176
• 7 Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, Sanford SchwartzJ, Taylor Thompson B, Popovich J, Hobbins TE, Spera MA, Alavi A, Terrin ML. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240-1245
• 8 Nand S, Fischer SG, Salgia R, Fisher RI. Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol 1987; 05: 1998-2003
• 9 Nanninga PB, van TeunenbroekA, Veenhof CHN, Büller HR, ten CateJW. Low prevalence of coagulation and fibrinolytic activation in patients with primary untreated cancer. Thromb Haemostas 1990; 64: 361-364
• 10 Luzzatto G, Schafer AI. The prethrombotic state in cancer. Semin Oncol 1990; 17: 147-159
• 11 Prandoni P, Lensing AWA, Büller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, ten CateJW. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-1133
• 12 Shen VS, Poliak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?. South Med J 1980; 73: 841-843
• 13 Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg 1992; 127: 310-313
• 14 Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen: a study of 159 patients. Cancer 1984; 54: 1264-1268
• 15 Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Htyniuk W, De PauwS. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318: 404-407
• 16 Lokich JJ, Becker B. Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer 1983; 52: 1586-1589
• 17 Bern MM, Bothe Jr A, Bistrian B, Champagne CD, Keane MS, Blackburn GL. Prophylaxis against central vein thrombosis with low-dose warfarin. Surgery 1986; 99: 216-221
• 18 European Consensus Statement. Prevention of venous thromboembolism. Intern Angiol 1992; 11: 151-159
• 19 Gallus A, Cade J, Ockelford P, Hepburn S, Maas M, Magnani H, Bucknall T, Stevens J, Porteous F. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicenter comparison. Thromb Haemostas 1993; 70: 562-567
• 20 Godwin J. Use of low molecular weight heparins in malignancy-related thromboembolic disorders: a clinical review. Clin Appl Thrombosis/Hemostasis 1996; 02 (Suppl. 01) 28-34
• 21 Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallbook T, Hedberg M, Horn A, Kelty E, Kvitting P, Lindhagen A, Ljungstrom KG, Matzsch T, Risberg B, Syk I, Torngren S, Wellander E, Ortenwall P. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients. Br J Surg 1995; 82: 496-501
• 22 Levine MN, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard KI, Steward D, Goodwin P. Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-889
• 23 Bern MM, Lokich JJ, Wallach SR, Bothe A Jr, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C. Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med 1990; 112: 423-428
• 24 Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A. Upper extremity deep venous thrombosis in cancer patients with venous access devices. Prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemostas 1996; 75: 251-253
• 25 Hirsh J, Salzman EW, Marder VJ. Treatment of venous thromboembolism. In Colman RW, Hirsh J, Marder VJ, Salzman EW. (edit) Hemostasis and Thrombosis, basic principles and clinical practice. JB Lippineott Company; Philadelphia: 1993: 1346-1366
• 26 Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bemardi E, Prins MH. The longterm clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 01-07
• 27 The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism. Submitted.
• 28 Zacharski LR, Henderson WG, Forman WB, Edwards RL, Cornell CJ, Forcier RJ, Headley E, Kim S, O’Donnell JF, O’Dell R, Tornyos K, Kwaan HC. Bleeding complications from warfarin anticoagulation in patients with malignancy. J Med 1985; 16: 535-561
• 29 Bona RD, Sivjee KY, Hickey AD, Wallace DM, Wajcs SB. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemostas 1995; 74: 1055-1058
• 30 Zacharski LR, Henderson WG, Rickies FR, Forman WB, Cornell Jr CJ, Forcier RJ, Edwards RL, Headley E, Kim SH, O’Donnell JR, O’Dell RO, Tornyos K, Kwaan HC. Effect of warfarin on survival in small cell carcinoma of the lung. JAMA 1981; 245: 831-835
• 31 Prandoni P, Lensing AWA, Büller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-445
• 32 Hull RD, Raskob GL, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lemer RG, Hall J, Sparling T, Brettell JN, Carter CJ, George R, Merli G, Ward J, Mayo W, Rosenbloom D, Brant R. Subcutaneous low molecular-weight heparin compared with intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-982
• 33 Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992; 339: 1476